Appareil pulmonaire CheckMate 816 (CA209-816) Randomized, OpenLabel, Phase 3 Trial of Nivolumab and Ipilimumab Versus Platinum Doublet Chemotherapy in Early Stage NSCLC. Paris
Mélanome uvéal et tumeurs oculaires CLXS196X2101 A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma Paris SOPHIE PIPERNO-NEUMANN
Sein métastatique RH+ COMPLEEMENT-1 An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease. Paris, Saint-Cloud PAUL-HENRI COTTU, FLORENCE LEREBOURS
Appareil pulmonaire BR.31 (IFCT1401) A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer Paris
Sein métastatique RH+ PADA-1 Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HTdriven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients. Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD
Sein Adjuvant PENELOPE-B An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease. Paris, Saint-Cloud PAUL-HENRI COTTU, ETIENNE BRAIN
Sein métastatique RH+ SAFIR PI3K A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer Paris, Saint-Cloud
Sein métastatique RH+ SAFIR-TOR Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women. Paris, Saint-Cloud PAUL-HENRI COTTU
Recherches "plusieurs pathologies" SHIVA02 (IC 2016-06) Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control. Paris, Saint-Cloud CHRISTOPHE LE TOURNEAU
VADS TOPNIVO - ORL09 A Safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN). Paris CHRISTOPHE LE TOURNEAU